Status:
COMPLETED
Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion
Lead Sponsor:
Hayatabad Medical Complex
Conditions:
Central Retinal Vein Occlusion With Macular Edema
Eligibility:
All Genders
40-80 years
Phase:
NA
Brief Summary
To compare the effect of intravitreal-Bevacizumab and Triamcinolone with intravitreal-Bevacizumab alone on visual acuity and central foveal thickness in patients with macular edema secondary to centra...
Eligibility Criteria
Inclusion
- Subjects of either gender, age 40-80 years, having macular edema secondary to CRVO, Best-corrected visual acuity (BCVA) of less than or equal to 0.3 on Log MAR chart (Snellen equivalent of 6/12), Central foveal thickness CFT greater than or equal to 250 microns on Heidelberg Spectralis Spectral Domain Optical coherence tomography (SD-OCT) and clinical diagnosis of CRVO.
Exclusion
- previously received laser treatment and/or intravitreal injection of any Anti-VEGF agent, having one eye, diagnosed case of glaucoma, family history of glaucoma, young patient, and anyone who has received any treatment for CRVO before presenting to us.
Key Trial Info
Start Date :
June 10 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 10 2018
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04812977
Start Date
June 10 2018
End Date
December 10 2018
Last Update
October 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hayatabad Medical Complex
Peshawar, KPK, Pakistan, 25000